Share this video  

ASCO GI 2024 | Biomarker analyses from CheckMate 648

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses findings from a biomarker analysis of the Phase III CheckMate 648 (NCT03143153) trial, which investigated the use of nivolumab with chemotherapy (chemo) and nivolumab with ipilimumab in previously untreated advanced esophageal squamous cell carcinoma (ESCC). Whole exome sequencing (WES) and RNA sequencing were used to assess tumor mutational burden (TMB) and gene expression signatures (GES). Results indicate that nivolumab + chemo and nivolumab + ipilimumab show superior overall survival (OS) compared to chemo alone in various biomarker subgroups. Higher inflammation and lower β-catenin GES scores were associated with improved OS benefit. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.